Zoetis Provides Units for Use in Regenerative Drugs Therapies to its Rising Equine Portfolio

PARSIPPANY, NJ, June 1, 2021 / PRNewswire / – Zoetis Inc., the world’s leading animal health company, announced that it has expanded its portfolio of equine care products to include Pro-Stride® APS, Restigen® PRP and CenTrate® BMA, a range of devices used to treat injuries caused by Horses are common and can lead to lameness.

Lameness in horses as a result of musculoskeletal pain, particularly osteoarthritis, is a major cause of veterinary examination1 and can have a significant impact on the physical, economic and quality of life for both the horse and the owner. Equine joint health care is an increasingly important area in equine medicine2.

These stable-side devices offer the possibility to use the natural healing mechanisms of a horse to treat joint and soft tissue diseases. A great advantage of using these devices is the ease with which the horse’s blood or bone marrow can be processed in the stable, which enables immediate use within 15-20 minutes of centrifugation; there is no need for incubation or preparation off-site.

“A healthy horse means more time in the saddle. Zoetis is committed to delivering solutions you can rely on through continuous innovation across the grooming continuum,” said Jeannie Jeffery, Vice President, US Equine at Zoetis. “The addition of Pro-Stride APS, Restigen PRP and Centrate BMA expands our ability to provide equine veterinarians with additional options to improve joint and soft tissue care and is an exciting demonstration of our commitment to horse health and wellbeing.”

Pro-Stride APS, Restigen PRP and Centrate BMA complete the constantly growing Zoetis family of horse care products. Zoetis will exclusively sell these products to veterinarians through key sales partners. For more information, please call Zoetis Customer Service at 1-888-Zoetis1 (1-888-963-8471).

About Zoetis
As the world’s leading animal health company, Zoetis has a single goal: to benefit our world and humanity by promoting animal care. After nearly 70 years of innovative methods for predicting, preventing, detecting and treating animal diseases, Zoetis continues to serve those who raise and care for animals worldwide – from ranchers to veterinarians and keepers. The company’s leading portfolio and pipeline of drugs, vaccines, diagnostics and technologies make a difference in over 100 countries. In 2020 Zoetis achieved sales of $ 6.7 billion with ~ 11,300 employees. More information is available at www.zoetis.com.

1.

USDA. 2000. Lameness and laminitis in US horses. USDA: APHIS: VS, CEAH, National Animal Health Monitoring System. Fort Collins, CO. # N318.0400.



2.

Velloso Alvarez, A, et al., A Survey of Clinical Use of Non-steroidal Intraarticular Therapeutics by Equine Practitioners. Front Vet Sci, 2020

All trademarks are owned by Zoetis Services LLC or one of its affiliates or licensors, unless otherwise stated. © 2021 Zoetis Services LLC. All rights reserved. GEQ-00751

Media contacts:
Colleen Cosgrove
Zoetis
862-217-3250
Colleen.cosgrove@zoetis.com

Lauren Klingler Tynan
609-213-3414
lauren.klinglertynan@mslgroup.com

View original content: http://www.prnewswire.com/news-releases/zoetis-adds-devices-for-use-in-regenerative-medicine-therapies-to-its-growing-equine-portfolio-301303068.html

SOURCE Zoetis Inc.